stoxline Quote Chart Rank Option Currency Glossary
SomaLogic, Inc. (SLGC)
2.1  -0.1 (-4.55%)    01-05 16:00
Open: 2.16
High: 2.31
Volume: 33,910,799
Pre. Close: 2.29
Low: 1.93
Market Cap: 396(M)
Technical analysis
2024-02-02 4:24:58 PM
Short term     
Mid term     
Targets 6-month :  2.96 1-year :  3.39
Resists First :  2.53 Second :  2.91
Pivot price 2.31
Supports First :  1.92 Second :  1.6
MAs MA(5) :  2.31 MA(20) :  2.35
MA(100) :  2.28 MA(250) :  2.54
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  25.8 D(3) :  39.3
RSI RSI(14): 39
52-week High :  3.78 Low :  1.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ SLGC ] has closed above bottom band by 18.6%. Bollinger Bands are 29.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.33 - 2.35 2.35 - 2.36
Low: 1.89 - 1.91 1.91 - 1.93
Close: 2.07 - 2.11 2.11 - 2.14
Company Description

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Headline News

Fri, 05 Jan 2024
SomaLogic gains stockholder nod for Standard BioTools deal By -

Thu, 28 Dec 2023
SomaLogic founder, CTO urge shareholders to vote against merger (NASDAQ:SLGC) - Seeking Alpha

Tue, 19 Dec 2023
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S - Simply Wall St

Mon, 11 Dec 2023
Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and ... - Barron's

Wed, 22 Nov 2023
With 54% ownership of the shares, SomaLogic, Inc. (NASDAQ:SLGC) is heavily dominated by institutional owners - Yahoo Finance

Sun, 12 Nov 2023
SomaLogic, Inc. (NASDAQ:SLGC) Q3 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Health Information Services
Shares Out 189 (M)
Shares Float 153 (M)
Held by Insiders 2.1 (%)
Held by Institutions 61.7 (%)
Shares Short 7,140 (K)
Shares Short P.Month 7,680 (K)
Stock Financials
EPS -0.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.63
Profit Margin -159.6 %
Operating Margin -108.6 %
Return on Assets (ttm) -14.2 %
Return on Equity (ttm) -23.8 %
Qtrly Rev. Growth -47.1 %
Gross Profit (p.s.) -0.06
Sales Per Share 0.43
EBITDA (p.s.) -0.72
Qtrly Earnings Growth 0 %
Operating Cash Flow -117 (M)
Levered Free Cash Flow -62 (M)
Stock Valuations
PE Ratio -3.05
PEG Ratio 0
Price to Book value 0.79
Price to Sales 4.84
Price to Cash Flow -3.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android